Press Releases |News

11/02/2020

Clinical Trials

Tempus Announces Strategic Collaboration with Janssen Applying Data Science to Enhance Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data...

09/16/2020

Clinical Trials

Tempus and LabCorp Announce Collaboration to Accelerate Clinical Trial Patient Participation

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus's TIME Trial® Network and the companies...

06/01/2020

Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...

05/31/2020

Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...

05/29/2020

Tempus TIME Trial™ Program Reaches Critical Scale and Operational Milestones

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....

03/16/2020

Clinical Trials

Tempus Announces the Addition of Dr. Kimberly Blackwell as Chief Medical Officer and Dr. Kenneth Carson as Vice President of Clinical Solutions

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announces the addition of Kimberly Blackwell, M.D., as Chief Medical Officer and Kenneth Carson, M.D., as Vice President of Clinical Solutions. “Our platform is designed to help clinicians make real-time,...

02/03/2020

New Genomics Technology Puts Precision Oncology into Practice at Rush

Rush University Medical Center is the first health care organization to launch medical record company Epic’s module for genomic results, giving providers the tools they need to tailor patient care at the molecular level. Rush will use the module as part of its Precision Oncology Center to...

12/12/2019

CVS Health Launches Transform Oncology Care™ Program to Help Improve Patient Outcomes and Lower Overall Costs

CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care...

12/11/2019

Tempus Announces the Acquisition of AKESOgen

CHICAGO and ATLANTA, December 11, 2019 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta. AKESOgen is an integrated...

09/30/2019

Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...

NEWS

Press Releases

Media Coverage

Additional Partnerships